AIkido Pharma Reports Filing for Expanded Worldwide Patent Coverage on Key Assets
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a status update on its expansion of key patent applications into several major ex-US territories worldwide.
For the Company's pancreatic cancer drug licensed from The University Texas at Austin, in which the Company currently seeks patent protection in the US, the Company will now also seek protection on the licensed drug formulation in China, India and the European Patent Office, with all member countries designated, which includes all 27 EU member countries plus 11 non-EU countries.
In connection with one of the two patent families relating to antiviral treatments licensed from University of Maryland, Baltimore (UMB), the Company filed a continuing patent application under the Patent Cooperation treaty, which will permit the Company seek patent protection simultaneously in the multitude of worldwide member countries. For the other patent family, the Company filed seeking to expand protection in the European Patent Office, designating all member countries.
Anthony Hayes, CEO of AIkido, stated, "Acquiring solid patent protection is the bedrock of drug asset ownership and essential to acquiring potential future market share in key countries around the world. At the appropriate times and when it makes economic sense, we will continue seeking to expand the territorial patent coverage on our licensed assets."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: [email protected]
www.haydenir.com
AIkido Pharma Inc.
Phone: 212-745-1373
Email: [email protected]
www.aikidopharma.com
SOURCE AIkido Pharma Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article